These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36517469)

  • 1. Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.
    Mu X; Cohen CA; Leung D; Rosa Duque JS; Cheng SMS; Chung Y; Wong HHW; Lee AMT; Li WY; Tam IYS; Lam JHY; Lee DHL; Chan SM; Tsang LCH; Chan KCK; Li JKC; Luk LLH; Chaothai S; Kwan KKH; Chu NC; Mori M; Jeevan T; Kandeil A; Webby RJ; Tu W; Valkenburg SA; Peiris M; Lau YL
    Signal Transduct Target Ther; 2022 Dec; 7(1):397. PubMed ID: 36517469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
    Lavender B; Hooker C; Frampton C; Williams M; Carson S; Paterson A; McGregor R; Moreland NJ; Gell K; Priddy FH; Wiig K; Le Gros G; Ussher JE; Brewerton M
    Vaccine; 2023 Aug; 41(38):5535-5544. PubMed ID: 37516574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents.
    Leung D; Cohen CA; Mu X; Rosa Duque JS; Cheng SMS; Wang X; Wang M; Zhang W; Zhang Y; Tam IYS; Lam JHY; Chan SM; Chaothai S; Kwan KKH; Chan KCK; Li JKC; Luk LLH; Tsang LCH; Chu NC; Wong WHS; Mori M; Leung WH; Valkenburg S; Peiris M; Tu W; Lau YL
    Front Immunol; 2023; 14():1106837. PubMed ID: 36949953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
    Liu Z; Alexander JL; Le K; Zhou X; Ibraheim H; Anandabaskaran S; Saifuddin A; Lin KW; McFarlane LR; Constable L; Seoane RC; Anand N; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HR; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N;
    EClinicalMedicine; 2023 Oct; 64():102249. PubMed ID: 37842172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
    Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
    Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
    Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
    Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
    Bruel T; Pinaud L; Tondeur L; Planas D; Staropoli I; Porrot F; Guivel-Benhassine F; Attia M; Pelleau S; Woudenberg T; Duru C; Koffi AD; Castelain S; Fernandes-Pellerin S; Jolly N; De Facci LP; Roux E; Ungeheuer MN; Van Der Werf S; White M; Schwartz O; Fontanet A
    EClinicalMedicine; 2022 Sep; 51():101576. PubMed ID: 35891947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.
    Lasagna A; Cassaniti I; Arena F; Bergami F; Percivalle E; Comolli G; Sarasini A; Ferrari A; Cicognini D; Schiavo R; Lo Cascio G; Pedrazzoli P; Baldanti F
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.
    Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Waterworth R; Umviligihozo G; Ennis S; Young L; Dong W; Kirkby D; Burns L; Leung V; Holmes DT; DeMarco ML; Simons J; Matic N; Montaner JSG; Brumme CJ; Prystajecky N; Niikura M; Lowe CF; Romney MG; Brockman MA; Brumme ZL
    Front Immunol; 2022; 13():947021. PubMed ID: 36148225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.
    Rosa Duque JS; Cheng SMS; Cohen CA; Leung D; Wang X; Mu X; Chung Y; Lau TM; Wang M; Zhang W; Zhang Y; Wong HHW; Tsang LCH; Chaothai S; Kwan TC; Li JKC; Chan KCK; Luk LLH; Ho JCH; Li WY; Lee AMT; Lam JHY; Chan SM; Wong WHS; Tam IYS; Mori M; Valkenburg SA; Peiris M; Tu W; Lau YL
    World J Pediatr; 2024 Apr; 20(4):353-370. PubMed ID: 38085470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.
    Basile K; Rockett RJ; McPhie K; Fennell M; Johnson-Mackinnon J; Agius JE; Fong W; Rahman H; Ko D; Donavan L; Hueston L; Lam C; Arnott A; Chen SC; Maddocks S; O'Sullivan MV; Dwyer DE; Sintchenko V; Kok J
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB.
    Chang ZW; Goh YS; Rouers A; Fong SW; Tay MZ; Chavatte JM; Hor PX; Loh CY; Huang Y; Tan YJ; Neo V; Kam IKJ; Yeo NK; Tan EX; Huang D; Wang B; Salleh SNM; Ngoh EZX; Wang CI; Leo YS; Lin RTP; Lye DCB; Young BE; Muthiah M; Ng LFP; Rénia L;
    Front Immunol; 2023; 14():1206016. PubMed ID: 37465685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous versus homologous boosting elicits qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients.
    Thompson EA; Ngecu W; Stoddart L; Johnston TS; Chang A; Cascino K; Alejo JL; Abedon AT; Samaha H; Rouphael N; Tobian AA; Segev DL; Werbel WA; Karaba AH; Blankson JN; Cox AL
    JCI Insight; 2023 May; 8(10):. PubMed ID: 37104041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents.
    Rosa Duque JS; Wang X; Leung D; Cheng SMS; Cohen CA; Mu X; Hachim A; Zhang Y; Chan SM; Chaothai S; Kwan KKH; Chan KCK; Li JKC; Luk LLH; Tsang LCH; Wong WHS; Cheang CH; Hung TK; Lam JHY; Chua GT; Tso WWY; Ip P; Mori M; Kavian N; Leung WH; Valkenburg S; Peiris M; Tu W; Lau YL
    Nat Commun; 2022 Jun; 13(1):3700. PubMed ID: 35764637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.
    Cheung PK; Lapointe HR; Sang Y; Ennis S; Mwimanzi F; Speckmaier S; Barad E; Dong W; Liang R; Simons J; Lowe CF; Romney MG; Brumme CJ; Niikura M; Brockman MA; Brumme ZL;
    AIDS; 2023 Apr; 37(5):F11-F18. PubMed ID: 36789806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.